As we can see from these illustrations, Australia will only have a 10% tariff with about USD$20bn of exports to the US. And that is before any negotiation. India with 26% on USD$88bn. Pharma, which is a big export, is exempted. IT will be impacted, but the volatility has created opportunities for investment in the sector. Notably for India, as compared to China and other Asian countries, it has fared better and provides them with a competitive advantage over many other Asian countries. These new tariffs could have the biggest impact on China, EU, Mexico, and Canada given the significant amount they export to the US.
Australia: Relatively low impact given lower level of exports to the US and lower tariffs
As we better understand the tariffs, we see that there are different levels of impact. For example, pharmaceuticals are exempted from tariffs so this could have a positive impact for our big pharma manufacturers. For those companies with US based manufacturing, we see this as a net positive, but for those manufacturing in high tariff countries and exporting to the US, this could hurt. Retailers importing from China could potentially get better rates as capacity frees up if we see China exports to the US fall. Added complexity in the global supply chain could benefit those with systems that help ease the additional complexity. The impact on banks could come from lower growth or higher defaults for companies exporting to the US, but no first order impacts from the tariffs. For metals and mining, the impact is more around 2nd order impacts on Chinese growth, based on what impacts the tariff could have. We believe REITS and infrastructure should benefit in a volatile environment. We have an Australian election coming up, which will be a big driver on growth and markets. The election result could also impact outcomes from negotiations with the US government on tariffs. In Australia, we view tariff and election uncertainty as a driver for higher volatility, for now.